Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

Publisher Name :
Date: 23-Apr-2019
No. of pages: 214
Inquire Before Buying

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline landscape.

Coronary artery disease (CAD) is the most common type of heart disease. CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage. The most common symptom of coronary artery disease is angina, or chest pain. Other symptoms include shortness of breath, palpitations, a faster heartbeat, weakness or dizziness, nausea and sweating.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 13, 6, 3, 18 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2019

Table of Contents
Introduction
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Products under Development by Companies, H1 2019
Products under Development by Universities/Institutes, H1 2019
Number of Products by Stage and Target, H1 2019
Number of Products by Stage and Mechanism of Action, H1 2019
Number of Products by Stage and Route of Administration, H1 2019
Number of Products by Stage and Molecule Type, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Ascendia Pharmaceuticals LLC, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by AstraZeneca Plc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Athera Biotechnologies AB, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Bayer AG, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cadrock Pty Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Capricor Therapeutics Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CardioVascular BioTherapeutics Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by CSL Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Cynata Therapeutics Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by DalCor Pharmaceuticals Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Gilead Sciences Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Hemostemix Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Human Stem Cells Institute, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Idorsia Pharmaceutical Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Kowa Co Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by LipimetiX Development Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Livzon Pharmaceutical Group Co Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by MedImmune LLC, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Orion Corp, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Proteon Therapeutics Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Resverlogix Corp, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Reven Pharmaceuticals Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Supernus Pharmaceuticals Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by The Medicines Company, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Verseon Corp, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by VESSL Therapeutics Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by ViroMed Co Ltd, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by Virtual Drug Development Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline by XyloCor Therapeutics Inc, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects, H1 2019
Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products, H1 2019

List of Figures
Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H1 2019
Number of Products under Development by Companies, H1 2019
Number of Products under Development by Universities/Institutes, H1 2019
Number of Products by Top 10 Targets, H1 2019
Number of Products by Stage and Top 10 Targets, H1 2019
Number of Products by Top 10 Mechanism of Actions, H1 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
Number of Products by Top 10 Routes of Administration, H1 2019
Number of Products by Stage and Top 10 Routes of Administration, H1 2019
Number of Products by Top 10 Molecule Types, H1 2019
Number of Products by Stage and Top 10 Molecule Types, H1 2019
  • Global Thoracic Surgery Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 118
    Market Overview of Global Thoracic Surgery market: According to our latest research, the global Thoracic Surgery market looks promising in the next 5 years. As of 2022, the global Thoracic Surgery market was estimated at USD 3777.06 million, and it's anticipated to reach USD 4689.46 million in 2028, with a CAGR of 3.67% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis of the global Thoracic Su......
  • Global Angina Pectoris Treatment Market Research Report 2024 (Status and Outlook)
    Published: 15-Dec-2023        Price: US 3200 Onwards        Pages: 125
    Report Overview: The Global Angina Pectoris Treatment Market Size was estimated at USD 8809.40 million in 2022 and is projected to reach USD 9981.15 million by 2029, exhibiting a CAGR of 1.80% during the forecast period. This report provides a deep insight into the global Angina Pectoris Treatment market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche marke......
  • Global Dilated Cardiomyopathy Therapeutics Market Status and Outlook 2023-2028
    Published: 22-Nov-2023        Price: US 3160 Onwards        Pages: 100
     Dilated cardiomyopathy is currently defined by the presence of left ventricular (LV) or biventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions (hypertension, valve disease) or coronary artery disease sufficient to cause global systolic impairment. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market value (million USD) data for ea......
  • Global Transcatheter Mitral Valve Replacement Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Sep-2023        Price: US 3380 Onwards        Pages: 112
    Market Overview of Global Transcatheter Mitral Valve Replacement market: According to our latest research, the global Transcatheter Mitral Valve Replacement market looks promising in the next 5 years. As of 2022, the global Transcatheter Mitral Valve Replacement market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a dee......
  • Global Thoracic Surgery Market Insights, Forecast to 2029
    Published: 14-Aug-2023        Price: US 4900 Onwards        Pages: 92
    Thoracic surgery is a procedure to treat medical conditions involving heart and lungs. It includes therapies such as redo heart surgery, aortic dissection for aortic surgery, minimally invasive mitral valve repair and replacement, and endovascular repair of thoracic aortic aneurysms. Market Analysis and Insights: Global Thoracic Surgery Market The global Thoracic Surgery market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth......
  • Global Angina Pectoris Treatment Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 29-Jun-2023        Price: US 3260 Onwards        Pages: 120
    The Angina Pectoris Treatment market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Angina Pectoris Treatment industry, and breaks down according to the type, application, and consumption area of Angina Pectoris Treatment. The report also introduces players in the industry from the perspective of the industry chain and marketing ......
  • Global Transcatheter Mitral Valve Replacement Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 15-Jun-2023        Price: US 3260 Onwards        Pages: 109
    The Transcatheter Mitral Valve Replacement market revenue was XX Million USD in 2022, and will reach XX Million USD in 2028, with a CAGR of XX% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Transcatheter Mitral Valve Replacement industry, and breaks down according to the type, application, and consumption area of Transcatheter Mitral Valve Replacement. The report also introduces players in the industry from the perspecti......
  • Global Angina Pectoris Treatment Market Size, Share and Industry Analysis by Regions, Countries, Types, and Applications, Forecast to 2028
    Published: 19-May-2023        Price: US 3480 Onwards        Pages: 105
    The global Angina Pectoris Treatment market size was valued at USD XX Million in 2022 and will reach USD XX Million in 2028, with a CAGR of XX% during 2022-2028. The Angina Pectoris Treatment market report covers sufficient and comprehensive data on market introduction, segmentations, status and trends, opportunities and challenges, industry chain, competitive analysis, company profiles, and trade statistics, etc. It provides in-depth and all-scale analysis of each segment of types......
  • Global Thoracic Surgery Market Insights: Impact of COVID-19 and Future Expectations to 2028
    Published: 16-May-2023        Price: US 3260 Onwards        Pages: 100
    The Thoracic Surgery market revenue was 3777.06 Million USD in 2022, and will reach 4689.46 Million USD in 2028, with a CAGR of 3.67% during 2022-2028. This report elaborates the market size, market characteristics, and market growth of the Thoracic Surgery industry, and breaks down according to the type, application, and consumption area of Thoracic Surgery. The report also introduces players in the industry from the perspective of the industry chain and marketing chain and descr......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs